Compare ADMA & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADMA | HTFL |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | 843 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2012 | N/A |
| Metric | ADMA | HTFL |
|---|---|---|
| Price | $7.92 | $29.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $25.67 | ★ $38.20 |
| AVG Volume (30 Days) | ★ 6.0M | 1.0M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $42,219,783.00 | N/A |
| Revenue This Year | $27.46 | $27.66 |
| Revenue Next Year | $22.11 | $23.55 |
| P/E Ratio | $43.03 | ★ N/A |
| Revenue Growth | ★ 43.85 | N/A |
| 52 Week Low | $7.21 | $20.13 |
| 52 Week High | $22.37 | $41.22 |
| Indicator | ADMA | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 30.12 | 51.32 |
| Support Level | $7.34 | $28.60 |
| Resistance Level | $16.02 | $32.71 |
| Average True Range (ATR) | 0.44 | 2.02 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 30.69 | 58.69 |
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.